GS-441524
GS-441524 是一种具有药理活性的三磷酸核苷分子的分子前体，是猫传染性腹膜炎病毒 feline infectious peritonitis virus (FIPV) 的有效抑制剂，其EC50值为0.78 μM。
GS-441524 Chemical Structure
CAS: 1191237-69-0
客户使用Selleck的发表文献7篇
产品质控
GS-441524相关产品
Antiviral抑制剂选择性比较
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| HuH7 | Function assay | 10 uM | 24 hrs | Cmax in human HuH7 cells assessed as triphosphate concentration per million cells at 10 uM incubated for 24 hrs measured after washout by LC-MS analysis, Cmax=0.0000176μM | 22446091 |
| Vero | Antiviral assay | 24 hrs | Antiviral activity against Parainfluenza 3 C 243 infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 24 hrs by MTS assay, EC50=1.71μM | 22446091 | |
| Vero | Antiviral assay | 24 hrs | Antiviral activity against SARS coronavirus Toronto-2 infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 24 hrs by MTS assay, EC50=2.24μM | 22446091 | |
| HuH7 | Antiviral assay | 24 hrs | Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as inhibition of virus induced cytopathic effect after 24 hrs by MTS assay, EC50=4.1μM | 22446091 | |
| Vero E6 | Antiviral assay | 24 hrs | Antiviral activity against Dengue virus type 2 New Guinea C infected in african green monkey Vero E6 cells assessed as inhibition of virus induced cytopathic effect after 24 hrs by MTS assay, EC50=9.46μM | 22446091 | |
| HeLa | Antiviral assay | 24 hrs | Antiviral activity against Yellow fever virus 17D infected in human HeLa cells assessed as inhibition of virus induced cytopathic effect after 24 hrs by MTS assay, EC50=11μM | 22446091 | |
| MDCK | Antiviral assay | 24 hrs | Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus induced cytopathic effect after 24 hrs by MTS assay, EC50=27.9μM | 22446091 | |
| Hep2 | Antiviral assay | 4 days | Antiviral activity against Respiratory syncytial virus A2 infected in human Hep2 cells assessed as reduction of virus-induced cytopathic effect after 4 days by Cell-Titer Glo assay, EC50=0.53μM | 28124907 | |
| HMVEC | Antiviral assay | 3 to 4 days | Antiviral activity against GFP-fused Ebolavirus infected in TERT-immortalized HMVEC assessed as reduction in viral replication preincubated with cells followed by viral infection measured after 3 to 4 days by fluorescence assay, EC50=0.78μM | 28124907 | |
| HuH7 | Antiviral assay | 3 days | Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7 cells preincubated with cells for 3 days followed by viral infection by luciferase assay, EC50=4.1μM | 28124907 | |
| HuH7 | Antiviral assay | 3 days | Antiviral activity against Ebolavirus infected in human HuH7 cells after 3 days by end point dilution assay, EC50=1.5μM | 28792763 | |
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | GS-441524 是一种具有药理活性的三磷酸核苷分子的分子前体，是猫传染性腹膜炎病毒 feline infectious peritonitis virus (FIPV) 的有效抑制剂，其EC50值为0.78 μM。 | ||
|---|---|---|---|
| 靶点 |
|
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05996744 | Recruiting | COVID-19 |
Gilead Sciences |
January 2024 | Phase 2|Phase 3 |
| NCT05715528 | Active not recruiting | COVID-19 |
Gilead Sciences |
February 8 2023 | Phase 3 |
| NCT05603143 | Terminated | COVID-19 |
Gilead Sciences |
November 5 2022 | Phase 3 |
| NCT04582266 | Completed | COVID-19 |
National Institute of Allergy and Infectious Diseases (NIAID)|Gilead Sciences |
March 31 2021 | -- |
| NCT04859244 | Completed | COVID-19 |
Copycat Sciences LLC |
January 1 2021 | Phase 1 |
| NCT04539262 | Completed | COVID-19 |
Gilead Sciences |
September 14 2020 | Phase 1|Phase 2 |
化学信息&溶解度
| 分子量 | 291.26 | 分子式 | C12H13N5O4 |
| CAS号 | 1191237-69-0 | SDF | -- |
| Smiles | C1=C2C(=NC=NN2C(=C1)C3(C(C(C(O3)CO)O)O)C#N)N | ||
| 储存条件(自收到货起) | 3年 -20°C 粉状 | ||
|
体外溶解度 |
DMSO : 58 mg/mL ( (199.13 mM)； DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
